Categories:
![](https://www.vitapharmaconsulting.com/en/wp-content/uploads/2022/04/IMAGEM-111.jpg)
cGMP requirements for Latin American drug products MA submissions – updated 18th May 2021
A marketing authorization submission represents a major effort for the pharmaceutical industry, and
Ler mais![](https://www.vitapharmaconsulting.com/en/wp-content/uploads/2022/04/IMAGEM-111.jpg)
Latin America – Regulatory Agencies
Latin America is increasingly raising interest from pharmaceutical companies in other regions. It is
Ler mais![](https://www.vitapharmaconsulting.com/en/wp-content/uploads/2022/04/107.png)
New Brazilian Regulatory Framework for API under Public Consultation
Approved by Anvisa’s Board of Directors, the Public Consultations of the New Regulatory Framew
Ler mais![](https://www.vitapharmaconsulting.com/en/wp-content/uploads/2022/04/IMAGEM-56.jpg)
EDQM- Published updated list of drafts of monographs for the European Pharmacopoeia
EDQM has published a statement with the updated list of substances which the drafts of its monograph
Ler mais